Around 45% of patients initially diagnosed with prostate cancer only have a slow-growing form of the cancer. In this case, active surveillance is recommended in order to treat only patients with aggressive prostate cancer.
With the protexam PSM test, aggressive prostate cancer can be detected at an early stage.